Regional Brain Measurement of Bmax and KD with the Opiate Antagonist Cyclofoxy: Equilibrium Studies in the Conscious Rat

Brain distribution of the opiate receptor antagonist, cyclofoxy (CF), was evaluated at equilibrium in rats. A combination of i.v. injection and constant i.v. infusion was used to administer CF over a wide dose range (2.4–450 nmol/rat). Kinetic simulations and experimental results showed that this administration schedule accomplishes “true” tissue-blood equilibrium of CF within 60 min. To estimate the receptor-ligand binding parameters, we assumed that the CF concentration at the receptor site is identical to that in plasma water at equilibrium, and can be calculated from measured blood data after corrections for radiolabeled metabolites and plasma protein binding. This assumption was supported by CSF and plasma water measurements at equilibrium. Regional KD, Bmax, and a nonspecific tissue binding equilibrium constant (Keq) were estimated by fitting the tissue and plasma water concentrations to a single receptor model; the estimated values were 1.4–2.9 nM, 15–74 pmol/g of tissue, and 5.2–8.0, respectively. They are in good agreement with previous in vitro measurements (Rothman and McLean, 1988) as well as in vivo estimates from i.v. injection experiments (Sawada et al., 1990c). The conventional method to estimate the receptor-ligand binding parameters using data from cerebellum to approximate nonspecific tissue binding was found to be unacceptable. Although cerebellum is a brain region with no opiate receptors in rats, small differences in nonspecific tissue binding in different brain regions resulted in significant overestimations of KD and Bmax with this method. Receptor-active and -inactive enantiomers [[18F](-)-CF and [3H](+)-CF)] were simultaneously administered to the same animal and the receptor-bound CF concentration could be accurately measured; this method was used to estimate 5max from a single study in a single animal and has potential for direct application in human studies using positron emission tomography.

[1]  K. B. Larson,et al.  Strategies for in vivo Measurement of Receptor Binding Using Positron Emission Tomography , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  Jonathan M. Links,et al.  Comparison of [11C]Diprenorphine and [11C]Carfentanil Binding to Opiate Receptors in Humans by Positron Emission Tomography , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  J. Korf,et al.  In vivo Binding of Spiperone and N-Methylspiperone to Dopaminergic and Serotonergic Sites in the Rat Brain: Multiple Modeling and Implications for PET Scanning , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  H. N. Wagner,et al.  Multicompartmental Analysis of [11C]-Carfentanil Binding to Opiate Receptors in Humans Measured by Positron Emission Tomography , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  R. Blasberg,et al.  Kinetic analysis of the opiate antagonist cyclofoxy in rat brain: simultaneous infusion of active and inactive enantiomers. , 1990, The Journal of pharmacology and experimental therapeutics.

[6]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[7]  C. Pert,et al.  Binding of radiolabeled opiates to slide-mounted sections of molded minced rat brain: A novel method for conducting radioreceptor assays , 1983, Neuropeptides.

[8]  K. Rice,et al.  A brief study of the selectivity of norbinaltorphimine, (−)-cyclofoxy, and (+)-cyclofoxy among opioid receptor subtypes in vitro , 1988, Neuropeptides.

[9]  A. Roos Intracellular pH and buffering power of rat brain. , 1971, The American journal of physiology.

[10]  K A Frey,et al.  Quantitative in vivo receptor binding. I. Theory and application to the muscarinic cholinergic receptor , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  W C Eckelman,et al.  S‐[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals , 1984, FEBS letters.

[12]  J M Links,et al.  Quantification of Neuroreceptors in the Living Human Brain. II. Inhibition Studies of Receptor Density and Affinity , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  C. Patlak,et al.  Kinetic Analysis of Transport and Opioid Receptor Binding of [3H](−)-Cyclofoxy in Rat Brain in vivo: Implications for Human Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  J. Kepler,et al.  A convenient procedure for preparing naltrexone‐15,16‐3H2 and naloxone‐15‐3H of high specific activity , 1976 .

[15]  C S Patlak,et al.  A method to obtain infusion schedules for prescribed blood concentration time courses. , 1976, Journal of applied physiology.

[16]  C. Pert,et al.  The pattern of [3H]cyclofoxy retention in rat brain after in vivo injection corresponds to the in vitro opiate receptor distribution , 1987, Brain Research.

[17]  Solomon H. Snyder,et al.  Autoradiographic localization of the opiate receptor in rat brain , 1975 .

[18]  Ronald G. Blasberg,et al.  Transport of α-Aminoisobutyric Acid across Brain Capillary and Cellular Membranes , 1983 .

[19]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[20]  B. W. Agranoff,et al.  Quantitative in vivo receptor binding , 1986 .

[21]  D. Graham,et al.  Quantitation of Photochemically Induced Focal Cerebral Ischemia in the Rat , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  G R Wilkinson,et al.  Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. , 1989, The Journal of clinical investigation.

[23]  R. Kawai,et al.  Simultaneous quantitation of lidocaine and its four metabolites by high-performance liquid chromatography: application to studies on in vitro and in vivo metabolism of lidocaine in rats. , 1985, Journal of pharmaceutical sciences.

[24]  S. Larson,et al.  Kinetic Analysis of 3-Quinuclidinyl 4-[125] Iodobenzilate Transport and Specific Binding to Muscarinic Acetylcholine Receptor in Rat Brain In Vivo , 1989 .

[25]  L. Farde,et al.  Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  R. Rothman,et al.  An examination of the opiate receptor subtypes labeled by [3H]cyclofoxy: An opiate antagonist suitable for positron emission tomography , 1988, Biological Psychiatry.

[27]  A. Gjedde,et al.  Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  J S Fowler,et al.  Kinetic Modeling of Receptor‐Ligand Binding Applied to Positron Emission Tomographic Studies with Neuroleptic Tracers , 1987, Journal of neurochemistry.

[29]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[30]  W C Eckelman,et al.  Radiosynthesis of [18F]3-acetylcyclofoxy: a high affinity opiate antagonist. , 1985, The International journal of applied radiation and isotopes.